查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1969872

全球流感疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Influenza Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

流感疫苗市場預計將從 2025 年的 95.8 億美元成長到 2034 年的 178.8 億美元，2026 年至 2034 年的複合年成長率為 7.18%。

由於人們對季節性流感預防的意識不斷提高，全球流感疫苗市場持續穩定成長。世界各國政府和衛生組織每年都會進行疫苗接種宣傳活動，以減少與流感相關的住院和死亡病例。流感病例的增加和大流行的風險促使醫療衛生系統加強疫苗接種計劃。疫苗研發技術的進步，包括細胞培養疫苗和重組疫苗，也推動了市場擴張。

推動疫苗接種率上升的主要因素之一是醫療保健和疫苗接種率的日益重視。老年人、兒童和慢性疾病患者等高風險族群需要定期接種流感疫苗。政府撥款、公共衛生措施以及低溫運輸基礎設施的改善正在加強疫苗供應系統。此外，製藥公司也加大研發投入，以提高疫苗的有效性和產能。

未來幾年，隨著全球疫苗接種率的提高，市場預計將穩定成長。新興經濟體醫療保健覆蓋範圍的擴大將創造新的成長機會。通用流感疫苗的創新和快速生產方法的開發將進一步增強該行業實力。隨著全球衛生基礎設施建設成為優先事項，全球流感疫苗市場預計將保持穩定、長期的成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球流感疫苗市場：依疫苗類型分類

  • 市場分析、洞察與預測
  • 去活化疫苗
  • 減毒活病毒疫苗

第5章：全球流感疫苗市場：依適應症分類

  • 市場分析、洞察與預測
  • 四價
  • 三價

第6章：全球流感疫苗市場：依年齡層別分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人

第7章：全球流感疫苗市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 注射
  • Nasal Spray

第8章 全球流感疫苗市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院和藥房
  • 向政府和機構供應
  • 其他

第9章 全球流感疫苗市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • GSK Plc
    • Pfizer Inc
    • Vaxess Technologies Inc
    • Merck & Co. Inc
    • Viatris Inc
    • Osivax
    • AstraZeneca Plc
    • Sinovac Biotech Ltd
    • CSL Limited
    • Emergent BioSolutions Inc
    • Emergex Vaccines Holding Ltd
簡介目錄
Product Code: VMR112110532

The Influenza Vaccine Market size is expected to reach USD 17.88 Billion in 2034 from USD 9.58 Billion (2025) growing at a CAGR of 7.18% during 2026-2034.

The Global Influenza Vaccine Market is witnessing consistent growth due to increasing awareness about seasonal flu prevention. Governments and health organizations worldwide conduct annual vaccination campaigns to reduce flu-related hospitalizations and deaths. Rising cases of influenza outbreaks and the risk of pandemics are pushing healthcare systems to strengthen immunization programs. Technological advancements in vaccine development, including cell-based and recombinant vaccines, are also supporting market expansion.

One of the main drivers is the growing emphasis on preventive healthcare and immunization coverage. High-risk groups such as elderly individuals, children, and patients with chronic diseases require regular flu vaccination. Government funding, public health initiatives, and improved cold chain infrastructure are enhancing vaccine distribution. Additionally, pharmaceutical companies are investing in research and development to improve vaccine effectiveness and production capacity.

In the coming years, the market is expected to grow steadily with improved global vaccination rates. Expanding healthcare access in emerging economies will create new growth opportunities. Innovations in universal flu vaccines and faster production methods may further strengthen the industry. As global health preparedness becomes a priority, the influenza vaccine market is likely to maintain stable and long-term growth worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

  • Inactivated
  • Live Attenuated

By Indication

  • Quadrivalent
  • Trivalent

By Age Group

  • Pediatric
  • Adult

By Route of Administration

  • Injection
  • Nasal Spray

By Distribution Channel

  • Hospitals & Pharmacies
  • Government & Institutional Supply
  • Others

COMPANIES PROFILED

  • GSK plc, Pfizer Inc, Vaxess Technologies Inc, Merck Co Inc, Viatris Inc, Osivax, AstraZeneca plc, Sinovac Biotech Ltd, CSL Limited, Emergent BioSolutions Inc, Emergex Vaccines Holding Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL INFLUENZA VACCINE MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Vaccine Type
  • 4.2. Inactivated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Live Attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL INFLUENZA VACCINE MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Indication
  • 5.2. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Trivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL INFLUENZA VACCINE MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Age Group
  • 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL INFLUENZA VACCINE MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

  • 7.1. Market Analysis, Insights and Forecast Route Of Administration
  • 7.2. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.3. Nasal Spray Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL INFLUENZA VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospitals & Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.3. Government & Institutional Supply Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL INFLUENZA VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.2.1 By Vaccine Type
    • 9.2.2 By Indication
    • 9.2.3 By Age Group
    • 9.2.4 By Route Of Administration
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.3.1 By Vaccine Type
    • 9.3.2 By Indication
    • 9.3.3 By Age Group
    • 9.3.4 By Route Of Administration
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.4.1 By Vaccine Type
    • 9.4.2 By Indication
    • 9.4.3 By Age Group
    • 9.4.4 By Route Of Administration
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.5.1 By Vaccine Type
    • 9.5.2 By Indication
    • 9.5.3 By Age Group
    • 9.5.4 By Route Of Administration
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.6.1 By Vaccine Type
    • 9.6.2 By Indication
    • 9.6.3 By Age Group
    • 9.6.4 By Route Of Administration
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL INFLUENZA VACCINE INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 GSK Plc
    • 11.2.2 Pfizer Inc
    • 11.2.3 Vaxess Technologies Inc
    • 11.2.4 Merck & Co. Inc
    • 11.2.5 Viatris Inc
    • 11.2.6 Osivax
    • 11.2.7 AstraZeneca Plc
    • 11.2.8 Sinovac Biotech Ltd
    • 11.2.9 CSL Limited
    • 11.2.10 Emergent BioSolutions Inc
    • 11.2.11 Emergex Vaccines Holding Ltd